We have located links that may give you full text access.
Characterization of lesions undergoing ischemia-driven revascularization after complete revascularization versus culprit lesion only in patients with STEMI and multivessel disease - A DANAMI-3-PRIMULTI substudy.
EuroIntervention 2019 January 23
AIMS: Treatment of the infarct-related artery only (IRA-only) in ST-segment elevation myocardial infarction (STEMI) is associated with a significantly higher rate of ischemia-driven revascularization (ID-RV) during follow-up than fractional flow reserve-guided complete revascularization (FFR-CRV).
METHODS AND RESULTS: In this study, we characterized the lesions that underwent ID-RV in the DANAMI-3-PRIMULTI-trial (n=627) with respect to location, angiographic diameter stenosis and functional significance. Rates of admission for suspected cardiac ischemia (17%) were similar in both groups; however, ID-RV was significantly less frequent in the FFR-CRV group than in the IRA-only group (5% vs. 17%; p<0.001). In both groups, the primary reason for ID-RV were non-culprit, non-treated lesions (N=71/82 lesions in IRA-only; N=13/26 in FFR-CRV). De-novo lesions or revascularization of previously treated lesions were rarely causes of ID-RV. In the IRA-only group, there was a trend towards a higher ID-RV-rate for lesions with a higher stenosis grade and located in more proximal segments - in particular ≥80% stenosis of left anterior descending and right coronary artery also led to angina class IV/unstable angina. In the FFR-CRV group, a FFR-value ≤0.80 showed to be an appropriate threshold for revascularization.
CONCLUSIONS: FFR-CRV in STEMI is associated with a significantly lower rate of ID-RV at follow-up than treatment of the IRA-only - this due to a difference in non-culprit, non-treated lesions between both groups and not in de-novo lesions or repeat revascularization of previously treated lesions. Further considerations are warranted in case of high-grade non-culprit stenosis at proximal coronary segments, borderline FFR-values and/or anticipated complex PCI.
METHODS AND RESULTS: In this study, we characterized the lesions that underwent ID-RV in the DANAMI-3-PRIMULTI-trial (n=627) with respect to location, angiographic diameter stenosis and functional significance. Rates of admission for suspected cardiac ischemia (17%) were similar in both groups; however, ID-RV was significantly less frequent in the FFR-CRV group than in the IRA-only group (5% vs. 17%; p<0.001). In both groups, the primary reason for ID-RV were non-culprit, non-treated lesions (N=71/82 lesions in IRA-only; N=13/26 in FFR-CRV). De-novo lesions or revascularization of previously treated lesions were rarely causes of ID-RV. In the IRA-only group, there was a trend towards a higher ID-RV-rate for lesions with a higher stenosis grade and located in more proximal segments - in particular ≥80% stenosis of left anterior descending and right coronary artery also led to angina class IV/unstable angina. In the FFR-CRV group, a FFR-value ≤0.80 showed to be an appropriate threshold for revascularization.
CONCLUSIONS: FFR-CRV in STEMI is associated with a significantly lower rate of ID-RV at follow-up than treatment of the IRA-only - this due to a difference in non-culprit, non-treated lesions between both groups and not in de-novo lesions or repeat revascularization of previously treated lesions. Further considerations are warranted in case of high-grade non-culprit stenosis at proximal coronary segments, borderline FFR-values and/or anticipated complex PCI.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app